The Smith group showed that treatment with a competitive CCK receptor (CCKAR) antagonist suppressed tumor initiation in non-obese KC mice and that HFD feeding could promote tumor growth in a CCKAR-dependent manner in an orthotopic transplant model (Smith et al, 2014; Nadella et al, 2018). The gene discussed is CCKAR; the disease is keratoconus.